BRPI0914123A2 - antagonistas de rna que alvejam hsp27 - Google Patents

antagonistas de rna que alvejam hsp27

Info

Publication number
BRPI0914123A2
BRPI0914123A2 BRPI0914123A BRPI0914123A BRPI0914123A2 BR PI0914123 A2 BRPI0914123 A2 BR PI0914123A2 BR PI0914123 A BRPI0914123 A BR PI0914123A BR PI0914123 A BRPI0914123 A BR PI0914123A BR PI0914123 A2 BRPI0914123 A2 BR PI0914123A2
Authority
BR
Brazil
Prior art keywords
antagonists targeting
rna antagonists
hsp27
targeting hsp27
rna
Prior art date
Application number
BRPI0914123A
Other languages
English (en)
Inventor
Jesper Worm
Original Assignee
Enzon Pharmaceuticals Inc
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc, Santaris Pharma As filed Critical Enzon Pharmaceuticals Inc
Publication of BRPI0914123A2 publication Critical patent/BRPI0914123A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0914123A 2008-07-02 2009-07-01 antagonistas de rna que alvejam hsp27 BRPI0914123A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7758808P 2008-07-02 2008-07-02
EP08104612 2008-07-02
PCT/IB2009/052860 WO2010001349A1 (en) 2008-07-02 2009-07-01 Rna antagonists targeting hsp27

Publications (1)

Publication Number Publication Date
BRPI0914123A2 true BRPI0914123A2 (pt) 2015-10-20

Family

ID=41092176

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914123A BRPI0914123A2 (pt) 2008-07-02 2009-07-01 antagonistas de rna que alvejam hsp27

Country Status (13)

Country Link
US (1) US8440809B2 (pt)
EP (1) EP2307029A1 (pt)
JP (1) JP2011526494A (pt)
KR (1) KR20110025863A (pt)
CN (1) CN102203255A (pt)
AU (1) AU2009265194A1 (pt)
BR (1) BRPI0914123A2 (pt)
CA (1) CA2728762A1 (pt)
EA (1) EA201170127A1 (pt)
IL (1) IL210411A0 (pt)
MX (1) MX2011000100A (pt)
TW (1) TW201014594A (pt)
WO (1) WO2010001349A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013114339A1 (en) 2012-02-02 2013-08-08 The Universityof British Columbia Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates
AU2014300981B2 (en) * 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9
US11514361B2 (en) 2019-08-30 2022-11-29 International Business Machines Corporation Automated artificial intelligence radial visualization

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703229B (zh) 2002-10-02 2011-01-05 英属哥伦比亚大学 治疗前列腺和其他癌的组合物和其制备药物的用途
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
SI3342425T1 (sl) * 2003-09-09 2020-04-30 Geron Corporation Modificirani oligonukleotidi za inhibicijo telomeraze
US20090264502A1 (en) 2005-08-25 2009-10-22 Bennett C Frank Compositions and their uses directed to hsp27
US9381209B2 (en) 2007-03-05 2016-07-05 The University Of British Columbia Treatment of squamous cell carcinoma with HSP27 antisense oligonucleotides and radiotherapy

Also Published As

Publication number Publication date
CN102203255A (zh) 2011-09-28
JP2011526494A (ja) 2011-10-13
AU2009265194A1 (en) 2010-01-07
KR20110025863A (ko) 2011-03-11
EP2307029A1 (en) 2011-04-13
TW201014594A (en) 2010-04-16
EA201170127A1 (ru) 2011-08-30
WO2010001349A8 (en) 2010-03-11
MX2011000100A (es) 2011-02-25
CA2728762A1 (en) 2010-01-07
US8440809B2 (en) 2013-05-14
IL210411A0 (en) 2011-03-31
WO2010001349A1 (en) 2010-01-07
US20110144185A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
EP2329442A4 (en) PREDICTIVE GEOTEMPORAL TARGETING OF ADVERTISING CONTENT
BRPI0920648A2 (pt) Combinações pesticidas contendo sulfoxaflor
EP2263545A4 (en) sonographer
BRPI0914414A2 (pt) direcionamento de ad baseado no comportamento do usuário
DK2200646T3 (da) RNA-Vacciner
EP2309333A4 (en) TONER
BRPI0922158A2 (pt) nanoemulsões
BRPI0908785A2 (pt) Formulações herbicida
BRPI0919058A2 (pt) indicador biológico independente
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0906366A2 (pt) Inalador
EP2345935A4 (en) TONER
BRPI0914817A2 (pt) inalador
DE112009000578A5 (de) Reibahle
EP2284538A4 (en) Biosensor
EP2280284A4 (en) Biosensor
BRPI0914098A2 (pt) biosensor
DE112008003988A5 (de) Abstandsmesssystem
BRPI0906779A2 (pt) Inalador
EP2340271A4 (en) CONJUGATES OF POLYMER-BIOACTIVE SUBSTANCES
BRPI0906367A2 (pt) inalador
DK2103820T3 (da) Fikseringsenhed
EP2301442A4 (en) ULTRASOUND PROBE
DK2379722T3 (da) Ekspressionsvektor
BRPI0920872A2 (pt) Mutações relacionadas com heterose induzida.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.